These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28140096)

  • 1. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1S2):81-86. PubMed ID: 28140096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):81-6. PubMed ID: 11842393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M; Goldenberg DM; Siegel AB; Ketas JC; Ashe M; Fiore JM; Leonard JP
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: Ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1S2):105-112. PubMed ID: 28140083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
    Leonard JP; Goldenberg DM
    Oncogene; 2007 May; 26(25):3704-13. PubMed ID: 17530024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukemia.
    Nabhan C; Rosen ST
    Semin Oncol; 2002 Feb; 29(1S2):75-80. PubMed ID: 28140095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: an insider's historical perspective.
    Grillo-López AJ
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):9-16. PubMed ID: 11226006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in the treatment of diffuse large B-cell lymphomas.
    Coiffier B
    Semin Oncol; 2002 Feb; 29(1S2):30-35. PubMed ID: 28140089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1S2):25-29. PubMed ID: 28140088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD22 as a target of passive immunotherapy.
    Cesano A; Gayko U
    Semin Oncol; 2003 Apr; 30(2):253-7. PubMed ID: 12720147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma.
    Warren TL; Weiner GJ
    Semin Oncol; 2002 Feb; 29(1S2):93-97. PubMed ID: 28140098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab: Mechanism of action and resistance.
    Maloney DG; Smith B; Rose A
    Semin Oncol; 2002 Feb; 29(1S2):2-9. PubMed ID: 28140087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J; Wang P; Kendall R; Chen C; Hu S; Boone T; Juan T; Talvenheimo J; Montestruque S; Sun J; Elliott G; Thomas J; Ferbas J; Kern B; Briddell R; Leonard JP; Cesano A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and phase I and II trials of rituximab.
    Maloney DG
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):74-8. PubMed ID: 10561021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in classification and therapy of indolent B-cell malignancies.
    Kipps TJ
    Semin Oncol; 2002 Feb; 29(1S2):98-104. PubMed ID: 28140099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
    Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanuolides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
    Semin Oncol; 2002 Feb; 29(1S2):87-92. PubMed ID: 28140097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.